All In Biotech

Drug Trial Radar · NCT07565441

Drug-Drug Interactions of JMKX003142 in Healthy Participants

A Single-center, Non-randomized, Open-label, Self-controlled, Phase I Clinical Study to Evaluate Drug-Drug Interactions (DDI) of JMKX003142 Tablets in Chinese Healthy Participants.

Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

112

Planned (sponsor's estimate)

Start

May 11, 2026

Primary completion

Nov 15, 2026

Study completion Feb 28, 2027

Sponsor

Lead sponsor
JemincareIndustry
Sponsor type
Industry
Collaborators
Zhejiang Hangyu Pharmaceutical Co., Ltd.
First posted
May 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, non-randomized, open-label, self-controlled, Phase I clinical trial to evaluate the drug-drug interactions (DDI) of JMKX003142 tablets in healthy adult participants. The study consists of five cohorts (Cohorts 1, 2, 3, 4, and 5). A total of 24 participants are planned enrollment in each of Cohorts 1, 2, 3, and 5, while 16 participants are planned for Cohort 4.

Conditions

  • ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Interventions

  • JMKX003142 tabletsDrug

    3mg once daily (QD) on Day 1 and Day 7

  • Fluconazole CapsulesDrug

    400mg QD on Day 4, 200mg QD from Day 5 to Day 9

  • Cocktail Substrates (Midazolam Oral Solution, Rosuvastatin Calcium Tablets, and Digoxin Tablets)Drug

    Midazolam Oral Solution 2mg, Rosuvastatin Calcium Tablets 5mg and Digoxin Tablets 0.25mg QD on Day 1, Day 8 and Day 21

  • Cyclosporine Soft CapsulesDrug

    100 mg twice daily (BID) from Day 4 to Day 9

  • Omeprazole Enteric-coated TabletsDrug

    40mg QD from Day 4 to Day 8

  • Efavirenz TabletsDrug

    600mg QD from Day 4 to Day 12

  • JMKX003142 tabletsDrug

    6mg QD from Day 8 to Day 25

  • JMKX003142 tabletsDrug

    6mg QD on Day 1 and Day 8

  • JMKX003142 tabletsDrug

    6mg QD on Day 1 and Day 10

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) of JMKX003142 and its metabolitesTime frame: for 120 hours
  2. Area Under Curve (AUC) of JMKX003142 and its metabolitesTime frame: for 120 hours
  3. Maximum Plasma Concentration (Cmax) of Midazolam and its metabolitesTime frame: for 144 hours
  4. Area Under Curve (AUC) of of Midazolam and its metabolitesTime frame: for 144 hours
  5. Maximum Plasma Concentration (Cmax) of RosuvastatinTime frame: 144 hours
  6. Area Under Curve (AUC) of of RosuvastatinTime frame: for 144 hours
  7. Maximum Plasma Concentration (Cmax) of DigoxinTime frame: for 144 hours
  8. Area Under Curve (AUC) of DigoxinTime frame: for 144 hours

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.